罗氏(RHHBY.US)“奥妥珠单抗”获批治疗狼疮性肾炎

智通财经10-20

智通财经APP获悉，10月20日，罗氏(RHHBY.US)宣布奥妥珠单抗(商品名：Gazyva/Gazyvaro)获FDA批准新适应症，用于治疗正在接受标准治疗的活动性狼疮性肾炎(LN)成人患者。在第一年接受四次初始剂量治疗后，患者的治疗频率可更改为一年两次。该药物是首个获得FDA批准用于治疗狼疮性肾炎的CD20靶向疗法。FDA此次批准主要是基于II期NOBILITY研究和III期REGENCY...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2576852194?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-10-20 21:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2576852194","market":"fut","top_or_hot":-1,"title":"罗氏(RHHBY.US)“奥妥珠单抗”获批治疗狼疮性肾炎","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，10月20日，罗氏(RHHBY.US)宣布奥妥珠单抗(商品名：Gazyva/Gazyvaro)获FDA批准新适应症，用于治疗正在接受标准治疗的活动性狼疮性肾炎(LN)成人患者。在第一年接受四次初始剂量治疗后，患者的治疗频率可更改为一年两次。该药物是首个获得FDA批准用于治疗狼疮性肾炎的CD20靶向疗法。FDA此次批准主要是基于II期NOBILITY研究和III期REGENCY...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1357271.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>罗氏(RHHBY.US)“奥妥珠单抗”获批治疗狼疮性肾炎</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n罗氏(RHHBY.US)“奥妥珠单抗”获批治疗狼疮性肾炎\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-10-20 21:06 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1357271.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，10月20日，罗氏(RHHBY.US)宣布奥妥珠单抗(商品名：Gazyva/Gazyvaro)获FDA批准新适应症，用于治疗正在接受标准治疗的活动性狼疮性肾炎(LN)成人患者。在第一年接受四次初始剂量治疗后，患者的治疗频率可更改为一年两次。该药物是首个获得FDA批准用于治疗狼疮性肾炎的CD20靶向疗法。FDA此次批准主要是基于II期NOBILITY研究和III期REGENCY...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1357271.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03165","symbol_name":"华夏欧优股对冲","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1357271.html","article_id":"2576852194","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2576852194","pubTimestamp":1760965614,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，10月20日，罗氏宣布奥妥珠单抗获FDA批准新适应症，用于治疗正在接受标准治疗的活动性狼疮性肾炎成人患者。该药物是首个获得FDA批准用于治疗狼疮性肾炎的CD20靶向疗法。FDA此次批准主要是基于II期NOBILITY研究和III期REGENCY研究的积极结果。与此同时，奥妥珠单抗组的补体水平相较于标准治疗组也实现了具有临床意义的改善，并且抗dsDNA抗体、疾病活动度和炎症标志物水平也有所降低。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"03165":"华夏欧优股对冲","BK4007":"制药","RHHBY":"罗氏控股"},"translate_title":"Roche (RHHBY.US) \"Otuzumab\" approved for the treatment of lupus nephritis","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03165":0.6,"RHHBY":1.5},"content_text":"智通财经APP获悉，10月20日，罗氏(RHHBY.US)宣布奥妥珠单抗(商品名：Gazyva/Gazyvaro)获FDA批准新适应症，用于治疗正在接受标准治疗的活动性狼疮性肾炎(LN)成人患者。在第一年接受四次初始剂量治疗后，患者的治疗频率可更改为一年两次。该药物是首个获得FDA批准用于治疗狼疮性肾炎的CD20靶向疗法。FDA此次批准主要是基于II期NOBILITY研究和III期REGENCY研究的积极结果。REGENCY研究显示，奥妥珠单抗联合标准治疗(霉酚酸酯和糖皮质激素)组有46.4%的患者在第76周时实现了完全肾脏缓解(CRR)，而标准治疗组这一比例为33.1%(调整后差异为13.4%，95% CI：2.0%-24.8%；P=0.0232)。与此同时，奥妥珠单抗组的补体水平相较于标准治疗组也实现了具有临床意义的改善，并且抗dsDNA抗体、疾病活动度和炎症标志物水平也有所降低。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2576852194","isCrawlerRequest":true}